Genmab A/S (CPSE:GMAB) commences share repurchases on March 26, 2025, under the program mandated by the shareholders in the Annual General Meeting held on March 12, 2025. As per the mandate, the company is authorized to repurchase total nominal value of up to 10% of the share capital, such that the company?s holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital at any point of time. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ OMX Copenhagen A/S at the time of the acquisition. The authorization will be valid till March 11, 2030.

On March 25, 2025, the company announced a share repurchase program. Under the program, the company has entered into a non-discretionary instruction with Goldman Sachs International (?Bank?) to repurchase up to 2,200,000 shares, for DKK 4,000 million. The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025. As of March 25, 2025, the company holds 2,537,988 treasury shares.